English Version of Asian Blockbuster ‘Onmyoji’ Soft Launches in Canada, Australia, New Zealand and Scandinavia
NetEase (NASDAQ: NTES) today announced the soft launch of the English language version of its blockbuster mobile game Onmyoji in Canada, Australia, New Zealand, and Scandinavia (Norway, Finland, Sweden, Denmark, and Iceland). Now available in these select countries on the App Store and Google Play -- and coming soon to PC via Facebook Gameroom and Steam -- this anime-style mobile RPG features stunning 3D graphics, PvP and PvE battles, characters voiced by anime veterans, and more.
Players in Canada, Australia, New Zealand, and Scandinavia can download the game now at http://m.onelink.me/50ac6a19.
Debuting today, the soft launch trailer delves into the narrative of Onmyoji: http://neteasegames.link/onmyojitrailer.
Onmyoji took Asian countries by storm when it launched late last year, topping charts in China, Japan, and Korea with over 200 million downloads to date and winning the Google Play 2017 Award for Most Competitive Game in China. Now, after a closed beta period, the anime RPG is available in soft launch countries for mobile devices (iOS and Android). It will launch on PC (Facebook Gameroom and Steam) soon, offering players the ability to switch seamlessly between their mobile device and a PC using their same character.
Onmyoji features beautiful anime characters voiced by industry legends such as Rie Kugimiya (Full Metal Alchemist) and Jun Fukuyama (Code Geass), who journey to defeat malicious spirits and find balance between the human and spirit worlds in their role as onmyoji. As players defeat more powerful enemies, gain more friendly spirits (or shikigami) to fight by their side, and earn more amulets and experience, they can level up and customize their unique character.
Join in with your friends to experience the turn-based PvP or PvE combat and battle mysterious and powerful demons. Each character in Onmyoji, good or bad, has its own backstory and motivation whether driven by ferocious loyalty or poignant past trauma. Immerse yourself in the anime world of Onmyoji and learn of fascinating new characters and stories while journeying to become the most powerful onmyoji in the land.
Check out Onmyoji assets here: http://netease-na.com/news#brand-assets.
Connect with Onmyoji online at:
- Official Website: https://en.onmyojigame.com
- Facebook: https://www.facebook.com/Onmyojigame/
- Steam: http://store.steampowered.com/app/551170/Onmyoji/
- YouTube: https://www.youtube.com/channel/UCgHDGNxYhvXb_LlVd6RVRmQ
- Forum: https://forum.onmyojigame.com/
NetEase, Inc. (NASDAQ: NTES) is a leading internet technology company in China. Dedicated to providing online services centered around content, community, communication and commerce, NetEase develops and operates some of China's most popular PC-client and mobile games, advertising services, e-mail services and e-commerce platforms. In partnership with Blizzard Entertainment, Mojang AB (a Microsoft subsidiary) and other global game developers, NetEase also operates some of the most popular international online games in China. For more information, please visit: http://ir.netease.com/.
Kris Sharbaugh, +1-415-955-8500
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 23:30 | Tiedote
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 19:00 | Tiedote
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 18:53 | Tiedote
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 16:07 | Tiedote
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
WeQ Launches to Transform Mobile Ad Tech with Human Intelligence and Inclusivity24.4.2018 16:00 | Tiedote
WeQ, a mobile ad tech brand providing user acquisition and engagement services at a global scale, announced today its official launch. WeQ is driven by a forward-thinking, socio-economic movement striving to shift from an exclusive ‘I’ culture to a collaborative ‘We’ culture. Setting its sights on becoming a trusted leader in the mobile ad tech industry, WeQ combines innovative data-driven technology with the collective human intelligence of its accomplished team of mobile ad tech experts to empower companies to reach their goals. WeQ comes out of the gate armed with a strategic investment, having secured more than $50 million USD in internal funds and debt capital to accelerate an ambitious global growth path. The ad tech brand plans to use the funds as it undertakes an aggressive M&A strategy. Over the next 12-24 months, WeQ plans to acquire cutting-edge technologies from innovative ventures to expand its technological footprint and services, attract international talent, and enter n
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 15:17 | Tiedote
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme